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The development of effective chemotherapy and im-
proved techniques of radiation therapy offer the 
possibility of managing soft tissue sarcomas so that 
surgery may need to be less radical than in the past and 
amputation can be avoided. The low rates of local-
regional and systemic recurrence that have resulted 
O o h tissue sarcomas (STS) consist of at least 55 different 
types of malignant tumors that or iginate f rom the 
common connective tissues of the body (1,2). These are 
rare tumors, and only about 4,500 new cases are treated 
each year in the United States (3). Traditionally, the 
primary form of therapy for STS has been surgical 
removal, ranging f rom local excision through radical 
amputations (4,5). 
At present, controversy exists about the optimal therapy 
to control local regional disease in STS (6-9). Local 
recurrences occur in 80-100% of cases after excision 
biopsy, 50% after wide exision, 10-20% after radical local 
resection, and about 5% after amputation (5,10). For this 
reason, amputation is a commonly practiced surgical 
procedure. Soft tissue sarcomas recur locally because 
they spread by continuity through nerve fibers, muscle 
bundles, fascial planes, and along blood vessels. They 
also invade locally and directly into surrounding struc-
tures. Lymph node metastases occur in about 6% of 
cases (11). Local recurrence after earlier surgery is a 
poor prognostic factor, since about one third of patients 
wi th local recurrences have concomi tant systemic 
recurrence (12). 
The high incidence of local recurrence after surgery for 
sarcomas of the extremities has stimulated the use of 
innovative approaches that combine mult imodal i ty 
therapy with surgery (7-9). The combination of pre-
operative radiation and/or chemotherapy (13) has 
several advantages. It may add to local control by 
reducing the size of the primary tumor so that previously 
inoperable lesions can be excised surgically. However, 
before this type of therapy is undertaken, the probabil ity 
of producing tumor regression must be high. Such 
preoperative therapy may also increase the local-re-
gional control rate by retarding the growth of malignant 
from using innovative combinations of chemotherapy, 
radiation therapy, and conservative surgery encouraged 
us to use preoperative intraarterial adriamycin (dox-
orubicin) with or without radiation therapy for three 
cases of soft tissue sarcomas ofthe lower extremities. The 
rationale for this therapy is also discussed. 
cells that are shed dur ing surgery (9). The disadvantage 
of adjuvant therapy that begins after surgical resection is 
that it attacks relatively avascular cells that have been 
shed into a large wound during surgical resection. 
Therefore, these cells may not be as susceptible to 
radiotherapy and/or chemotherapy. 
Recently developed approaches to preoperative chemo-
therapy have been equally concerned with the impl i-
cations of blood borne metastatic disease in STS (7,9). 
Patients with sarcomas finally fail and die not because 
local control of the disease fails, but rather because 
systemic control fails. It is therefore appropriate that 
systemic control should receive the highest priority and 
should not be compromised by local control approaches. 
Golde calculated that spontaneous mutation to drug 
resistance may occur over relat ively few genera-
t ion times in micrometastases that contain 10% cells or 
more (14). It is probable, though uncertain, that the 
kinetic aggressiveness of micrometastases is greater than 
that of macrometastases. Therefore, the several months 
of delay in providing systemic treatment that sometimes 
occurs because of the t ime needed for surgery and 
recuperation may permit drug resistance to develop. 
Surgery and radiotherapy have major systemic effects 
that may compromise subsequent chemotherapy. 
Another advantage of preoperative multimodality therapy 
is that the responsiveness o f the tumor to chemotherapy 
and radiation therapy is established while the tumor is in 
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vivo. Studies both in head and neck cancer, and more 
definit ively in osteogenic sarcoma, suggest that the 
responsiveness of the tumor dur ing the initial pre-
operative treatment period may predict the responsive-
ness of microscopic disease to chemotherapy treatment 
given after surgical excision (15). 
A number of centers are current ly addressing the 
problem of mult imodality therapy for STS (7,9,15). The 
center at the University of California at Los Angeles 
(UCLA) has used intraarterial doxorubicin fol lowed by 
radiation of the tumor, which is fol lowed by resection 
and adjuvant systemic chemotherapy, since 1974 (17). 
Not only has this therapy improved the local and 
regional control rates (16), but it has also permitted limbs 
to be saved. In this way the major psychosocial compl i -
cations of amputation are avoided. Moreover, com-
pared to amputation alone, this approach has not 
adversely affected the prognosis (16). It has been 
effective both for primary and recurrent soft tissue 
sarcomas in the extremities (16). 
Based on the UCLA experience, we have initiated a 
protocol at Henry Ford Hospital to treat soft tissue 
sarcomas of the extremities. We modif ied the radiation 
dose after the UCLA center reported four long bone 
fractures fol lowing radiation therapy with 3,500 rads (17). 
We treated three cases wi th preoperative radiation 
and/or chemotherapy. Each was treated di f ferent ly 
because of special individual considerations. 
Case Reports 
Case 1 
A 17-year-old black girl presented wi th a painless 
enlarging left thigh mass that had been present for about 
20 months. The mass, which occupied the anterior and 
medial compartments of the th igh, measured 33 x 23 cm. 
It was f i rm, nontender, and not attached to underlying 
bone. A CAT scan (Fig. 1) revealed a large, soft tissue 
mass of varying tissue density which obliterated fascial 
planes between muscle groups. The mass involved the 
rectus femor is , sartorius, vastus medial is, and the 
adductor group, and it extended to wi th in 8 cm of the 
knee joint and wi th in 5 cm of the inguinal l igament. An 
arteriogram (Fig. 2) demonstrated a hypervascular mass 
with displacement of the femoral artery. An incision 
biopsy revealed a mal ignant hemangioper icy toma 
(Fig. 3). 
The patient was treated with preoperative chemotherapy 
that consisted of intraarterial doxorubicin (30 mg per 
day) by continuous infusion for 72 hours. She also 
received systemic v incr is t ine, ac t inomycin D, and 
Cytoxan. The tumor diminished by about 20% over the 
next month. At that t ime, a wide excision of the tumor 
was per formed, including the gracilis, the adductor 
Fig. 1. Case 1 
CAT scan th rough the middle of the tumor in the left th igh demon-
s t ra t ing extens ive i n v o l v e m e n t of t he med ia l and an te r i o r 
compartments. 
Fig. 2. Case 1 
Digital subtract ion angiogram (DSA) demonstrat ing displacement of 
the superficial femoral artery and marked vascularity of the tumor. 
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Fig. 3A. Case 1 
Histologic section (H + E stain) demonstrat ing many vascular spaces 
interspersed wi th spindle-shaped tumor cells consistent wi th malignant 
hemangioper icytoma. 
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Fig. 3B. Case 1 
Histologic section (reticulin stain) demonstrating hemangiopericytoma. 
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Fig. 4. Case 2 Fig. 5. Case 2 
CAT scan of the pelvis demonstrating large tumor adjacent to the pubic Pretreatment arteriogram demonstrating vascular mass adjacent to the 
bone compressing the bladder. wall of the true pelvis. 
- # t 
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Fig. 8. Case 3 
Histologic section ( H & E stain) demonstrating a histiocytic tumor. Some areas appear myxoid. 
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Fig. 6. Case 2 
Arter iogram four weeks after intraarterial adriamycin was administered 
demonstrat ing decreased size and vascularity of the tumor. 
compartment, sartorius, the vastus medialis, and the 
rectus femoris. The vastus lateralis, which was at least one 
fascial plane distant f rom the tumor, was left intact to 
stabilize the patella. The patella was also stabilized 
medially by sutur ing the tendon of the semimem-
branous muscle anteriorly to its superior border. One 
inch of the femoral artery was removed, and a primary 
end-to-end anastomosis was performed. 
The patient's postoperative course was complicated by a 
major skin slough which required three months of 
dressings and skin grafts. She received 5,400 rads of 
radiation in six weeks. Six months later, bilateral pu l -
monary metastases were noted, and systemic chemo-
the rapy cons is t ing of d o x o r u b i c i n and Cytoxan 
produced a partial response. The metastases were 
excised by staged bilateral thoracotomies eight and 12 
months after primary tumor resection. No local recur-
rence has been found 15 months after the patient's initial 
presentation, and she is walking unaided. 
Case 2 
A 70-year-old white woman presented with a recurrent 
hemangiopericytoma in the right groin. This tumor, first 
resected in 1970, had recurred in 1979. At that t ime the 
mass was excised, and she received 5,600 rads of radi-
ation postoperatively. 
She returned in October 1982 because of symptoms of 
obturator nerve compression. A 3 cm mass was found on 
CAT scan (Fig. 4). Arteriogram revealed a vascular tumor 
(Fig. 5) closely associated with the external iliac vessels 
on the right, but apparently supplied primarily by the 
branches of the internal iliac vessels. Intraarterial dox-
orubicin was administered through a catheter placed in 
the left axillary artery and ending just proximal to the 
right internal iliac artery. She received 85 mg of doxo-
rubicin over three days by continuous infusion. One 
month later the patient was readmitted, and the arterio-
gram was repeated (Fig. 6). The vascularity of the tumor 
had diminished markedly, and it was about 40% smaller. 
Previous radiation precluded further radiotherapy. In 
January 1983 the tumor was excised locally (Fig. 7). 
Internal hemipelvectomy and vascular reconstruction 
were rejected because of the patient's age and because 
of the relatively slow growing nature of this tumor. For 
similar reasons, postoperative adjuvant chemotherapy 
was also rejected. 
No evidence of recurrence has been found by clinical 
examination or CAT scan 13 months later. 
Fig. 7. Case 2 
Macroscopic appearance of the hemangioper icytoma at the t ime of 
operat ion. 
Case 3 
A 39-year-old white woman presented with pain and 
discomfort in the left thigh of four months' duration. 
When she was examined, a large tumor mass approxi-
mately 15 cm in diameter was found to occupy the 
medial upper aspect of the left th igh. Incision biopsy 
demonstrated a high-grade fibrous histiocytoma (Fig. 8), 
which by CAT scan was located in the adductor compart-
ment (Fig. 9). Arteriogram disclosed a hypervascular 
tumor (Fig. 10). 
The patient was treated with 90 mg of doxorubicin by 
continuous intraarterial route over 72 hours, with the t ip 
of the catheter placed in the external iliac artery. This 
therapy was fo l lowed by 1,750 rads of radiation to the 
thigh given for two weeks. The patient had noticeable 
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relief of her symptoms, and the tumor diminished by 
20% within three weeks. 
The tumor was then resected with clear margins, in-
c l u d i n g the en t i r e a d d u c t o r c o m p a r t m e n t w i t h 
obturator nerve and arteries. The tumor was not at-
tached to the bone and could be resected with a margin 
f rom the femoral vessels. An incontinuity lymph node 
dissection was also done. 
Histology of the tumor showed some necrosis. The 
patient had an uneventful recovery from the procedure 
and has completed adjuvant systemic chemotherapy 
with doxorubicin and Cytoxan. No evidence of local or 
systemic recurrence of the tumor has been found 12 
months after the patient's initial presentation. 
Discussion 
The three cases discussed represent our preliminary 
experience with a combinat ion of preoperative radi-
ation and/or chemotherapy to treat soft tissue sarcomas 
at Henry Ford Hospital. Despite the wound complication 
in Case 1, intraarterial doxorubicin was tolerated well in 
all three patients. Following the early UCLA experience 
(9), we placed the tip of the catheter in large arteries 
proximal to the tumor and avoided placing it close to 
small branches. The major disadvantage of this tech-
nique is that a large bolus of chemotherapy might be 
delivered to a small area of skin, subcutaneous tissue, 
muscle, and other normal tissues, which might result in 
tissue necrosis (9). To obviate this compl icat ion, cath-
eters placed carefully at the t ime of arteriography are 
secured by sutures in the skin at the point of entry into 
the vessel. Even so, because the t ip of the catheter may 
migrate for a few centimeters, we inject fluorescein into 
the catheter every six hours. We also examine the skin 
with a Woods lamp to ensure that no excessive staining 
of skin occurs in the distr ibution of small b lood vessels 
branching f rom the artery that contains the tip of the 
Fig. 9. Case 3 
CAT scan of the th igh demonstrat ing a tumor in the adductor 
compartment on the left. 
indwell ing catheter. On one occasion with Case 1 we 
had to reposition the catheter. 
Doxorubicin (adriamycin) is effective in soft tissue sar-
comas (18). Used as a single agent or in regimens that 
combine chemotherapeutic agents, the overall response 
rate for disseminated soft tissue sarcomas has been 
reported to be 34%. Other drugs, used as single agents 
with l imited efficacy against soft tissue sarcomas, have 
been added to doxorub ic in in sequential, nonran-
domized studies, with moderate improvement in the 
response rates and the length of survival (18). Because 
doxorubicin is beneficial in disseminated STS when used 
systemically, intraarterial techniques using this agent 
have been reexamined (9,19). Theoretically, this route of 
administration can minimize systemic toxicity and maxi-
mize local tumor destruction. Many neoplasms have 
been treated by intraarterial infusion of drugs, either 
alone or as an adjunct to surgery or radiation therapy 
(20,21). 
We selected intraarterial doxorubicin because of its 
known efficacy by the intravenous route, because metab-
olism of the drug may not be required for its antitumor 
effect (22), and because pharmacokinetic data in animals 
suggest that clearance rates fol lowing intravenous admin-
istration may vary considerably. Since doxorubicin binds 
avidly to DNA and causes disordered DNA funct ion, it is 
possible that even a single arterial transit of the drug 
through tumor tissue would result in substantial DNA 
binding, possibly many times greater than after in-
travenous administration. 
Studies with intraarterial doxorubicin (23) suggest that 
these theoretical advantages may in fact justify its clinical 
use. Al though good responses may have been achieved 
in STS using intravenous doxorubicin preoperatively, 
some investigators suggest that such good responses to 
intravenous administration are unusual (23). 
The toxicity of intraarterial doxorubicin has been toler-
able and similar to that reported with intravenous 
doxorubic in. Skin necrosis, such as occurred in our first 
patient, has also been reported. However, wi th increas-
ing use and experience, this problem can be avoided by 
more careful patient selection and improved surgical 
technique. At present, optimal doses of intraarterial 
doxorubicin are uncertain. The dose of 60-90 mg/m^ 
given over three days, selected from previously reported 
experience with intravenous doxorubic in, is tolerable 
and effective (23). 
All three of our patients treated with intraarterial doxo-
rubicin had some response. In Case 1, the d iminut ion in 
tumor size cannot be ascribed to intraarterial doxo-
rubicin alone since the patient received vincristine, 
actinomycin D, and Cytoxan as well . In Case 2, both the 
vascularity and the size of the tumor diminished. In Case 
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Fig. 10. Case 3 
Arter iogram demonstrat ing a hypervascular tumor suppl ied mainly by 
branches of the profunda femoris artery on the left. 
3, the dramatic symptomatic improvement may well 
have been due to a combinat ion of the intraarterial dox-
orubicin and radiation therapy. Systemic effects, seen in 
all three patients, included alopecia and leukopenia. 
None of the three complained of nausea or vomit ing, 
and none had mucositis or gastrointestinal side effects. 
Radiation is a potent form of therapy for soft tissue 
sarcomas. When radiation was combined with l imited 
surgery, the local control rate was better than 85% at the 
M.D. Anderson Hospital (24). Also,the incidenceof local 
recurrence after radiation therapy depends somewhat 
on the site; it is higher for proximal thigh and upper arm 
lesions than for those of the forearm and leg (24). The 
local recurrence rate also depends on the size of the 
tumor and is higher for tumors over 5 cm in diameter. 
Used alone, radiation provides local control in about 
60% of cases (25). When preoperative radiation was 
administered before surgery (7,9), the excised tumor was 
smaller, surrounded by a relatively dense pseudo-
capsule, and partially or totally necrotic. The local 
recurrence rate has been minimal when preoperative 
radiation therapy was fol lowed by wide excisional 
surgery (11). 
The classical treatment of STS is amputation or radical 
excision. Even with apparently adequate surgery, local 
recurrence rates are high (5,10), and approximately 80% 
of patients die of systemic disease, usually from pul -
monary metastasis (2-4,6). As chemotherapy for widely 
metastatic sarcoma developed successfully, the use of 
preoperative chemotherapy to treat STS began to appear 
possible, in the same way that preoperative chemo-
therapy is used to treat breast carcinoma (26). Although it 
is too soon to state whether or not preoperative systemic 
chemotherapy is of value for STS, initial studies suggest 
that it is beneficial (7,9,16). While each of three major 
therapeutic modalities used against STS is effective, none 
is capable of eradicating the disease completely. Accord-
ingly, all three treatments in combinat ion should be 
used. Initial results show an improved survival rate with a 
very small local recurrence rate (9,16). However, the 
optimal t iming and dose of chemotherapy and radiation 
as well as the best form of surgery have not yet been fully 
determined. 
The major benefits of preoperative mult imodal i ty 
therapy combined with l imb salvage surgery are the 
functional advantage of retaining a useful l imb and the 
psychosocial advantage of not having to confront a 
major amputation. Management of body disfigurement 
is always a major problem for both physician and patient. 
Of course, the primary concern is to cure disease even at 
the expense of incurr ing undesirable physical changes. 
With the combination of therapy used in our three cases, 
major disfigurement was avoided, and ultimate control 
of the disease was certainly no worse than would be 
anticipated with conventional therapy. In addit ion, our 
patients' rehabil itation improved considerably because 
they had functional use of their limbs (16). 
Patients with STS may now be offered a regimen of 
preoperative radiation and/or chemotherapy and limb 
salvage procedures as an alternative to radical ampu-
tat ion. Cont inued study of the advantages and disad-
vantages of both approaches is much needed. 
37 
Nathanson 
References 
1, Enter l ine HT, H is topa tho logy of sarcomas, Semin O n c o l 
1981;8:133-55, 
2, Hajdu SI, Pathology of soft tissue tumors, Philadelphia; Lea and 
Febiger, 1979, 
3, LJ,S, Department of Health, Education, and Welfare, Cancer 
patient survival. Report No, 5, Washington, D,C,; U,S, Department 
of Heal th, Education and Welfare, 1976 (NIH Publication Number 
77-992), 
4, Cerner RD, Moore GE, Pickren JW, Soft tissue sarcomas, Ann Surg 
1975:181:803-08, 
5, Shiu M H , Castro EB, Hajdu SI, Fortner JG, Surgical treatment of 297 
soft t issue sarcomas of the lower ex t rem i t y , Ann Surg 
1975;182:596-602. 
6, Sears HF, Soft tissue sarcoma: a historical overview, Semin Onco l 
1981;8:129-32, 
7, Rosenberg SA, Kent H, Costa J, et al. Prospective randomized 
evaluation of the role of l imb sparing surgery, radiation therapy 
and adjuvant chemoimmunotherapy in the treatment of adult 
soft-tissue sarcomas. Surgery 1978:83:62-9, 
8, Russell W O , Cohen J, Enzinger F, et al, A clinical and pathological 
staging system for soft tissue sarcomas. Cancer 1977;40:1562-70, 
9, M o r t o n DL, Eilber FR, Townsend C M , Jr,, et al. Limb salvage f rom a 
mult idiscipl inary treatment approach for skeletal and soft tissue 
sarcomas of the extremity, Ann Surg 1976;184:268-78, 
10, Simon ME,Ennek ingWF,The management of soft-tissue sarcomas 
of the extremities, J Bone Joint Surg 1976;58A:317-39, 
11, Weingrad DW, Rosenberg SA, Early lymphatic spread of osteo-
genic and soft tissue sarcomas. Surgery 1978;84;231-40, 
12, Cantin J, McNeer GP, Chu FC, et al. The prob lem of local 
recurrence after treatment of soft tissue sarcoma, Ann Surg 
1968;168:47-53, 
13, Frei E II I , Clinical cancer research: an embatt led species. Cancer 
1982;50:1979-92, 
14, Golde JH, A mathematical model for relating the drug sensitivity of 
tumors to their spontaneous mutat ion rate. Cancer Treatment 
Reports 1979;63:1727-36, 
15, Rosen G, Current management of malignant bone tumors. In : 
Burchenal JH and Oet tgen HF, eds. Cancer: Achievements, chal-
lenges, and prospects for the 1980's, Vol. I I , Grune and Stratton, 
1981:213, 
16, Mo r ton DL, Eilber FR, Weisenburger TH, Liu PY, Mul t imodal i ty 
therapy of malignant melanoma, skeletal and soft tissue sarcomas 
using immunotherapy, chemotherapy and radiation therapy. In : 
Salmon SE, Jones SE, eds. Adjuvant therapy of cancer I I I , Grune and 
Stratton, 1981:241-51, 
17, Mo r ton DL, Personal communicat ion, 
18, Pinedo H M , Kenis Y, Chemotherapy of advanced soft-tissue 
sarcomas in adults. Cancer Treatment Reports 1977;4:67-8, 
19, Karakousis CP, Lopez R, Catane R, Rao V, M o o r e R. Holyoke ED. 
Intraarterial Adr iamycin in the treatment of soft tissue sarcomas. J 
Surg Onco l 1980;13:21-7, 
Clinical trials wi th Adr iamycin, 20, M idd leman E, Luce J, Frei 
Cancer 1971;28:844-50, 
21, Wang JJ, Cortes E, Sinks LF, Hol land JF, Therapeutic effect and 
toxicity of Adriamycin in patients wi th neoplastic disease. Cancer 
1971;28:837-43, 
22, Rosso R, Ravazzoni C, Esposito M , Sala R, Santi L, Plasma and 
urinary levels of Adr iamycin in man, Eur J Cancer 1972;8:455-9, 
23, Haskell C M , Silverstein MJ, Rangel D M , Hunt JS, Sparks FC, 
M o r t o n DL, Mul t imoda l i t y cancer therapy in man: A pi lot study of 
Adr iamycin by arterial infusion. Cancer 1974;33:1485-90, 
24, Suit HD, Russell W O , Mar t in RG, Sarcoma of soft tissue: Clinical 
and histopathologic parameters and response to treatment. 
Cancer 1975:35:1478-83, 
25, McNeer GP, Cantin J, Chu F, et al. Effectiveness of radiation 
therapy in the management of sarcoma of the soft somatic tissues. 
Cancer 1968;22:391-7, 
26, Fisher B, Breast cancer studies of the NSABP: An editorial ized 
overview. In: Salmon SE, Jones SE, eds. Adjuvant Chemotherapy, 
Grune and Stratton, 1981:359, 
38 
